Skin Cancer News

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

Previous studies have demonstrated that melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.

Study Reveals Widespread Non-compliance With Indoor Tanning Regulations

Study Reveals Widespread Non-compliance With Indoor Tanning Regulations

Four hundred and twenty-seven tanning salons were contacted; 32.7% of contacted salons were non-compliant with their respective state's regulations.

FDA Grants Breakthrough Therapy Designation to Adjuvant Dabrafenib Plus Trametinib for Melanoma

FDA Grants Breakthrough Therapy Designation to Adjuvant Dabrafenib Plus Trametinib for Melanoma

Dabrafenib plus trametinib is the first adjuvant therapy indicated specifically for melanoma with the BRAFV600 mutation.

Study Reveals Factors Associated With Delays in Melanoma Treatment

Study Reveals Factors Associated With Delays in Melanoma Treatment

Researchers evaluated data from 7629 patients with melanoma included in the North Carolina cancer registry to determine relevant variables associated with delayed surgery.

ctDNA Sequencing Predicts Likelihood of Immunotherapy Response

ctDNA Sequencing Predicts Likelihood of Immunotherapy Response

Researchers collected ctDNA samples from patients with varying cancer types to determine whether liquid biopsies may help to predict response to checkpoint inhibition.

Propranolol May Prolong Disease-free Survival in Melanoma

Propranolol May Prolong Disease-free Survival in Melanoma

Previous studies demonstrated that propranolol may inhibit angiogenesis and migration of cancer cells, leading to a delay in disease progression.

Adjuvant Therapy With Dabrafenib Plus Trametinib May Provide Benefit in Melanoma

Adjuvant Therapy With Dabrafenib Plus Trametinib May Provide Benefit in Melanoma

Investigators randomly assigned 870 patients with advanced melanoma who had undergone complete resection to receive trametinib and dabrafenib vs placebo for 1 year.

Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention

Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention

The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.

FDA Grants Cemiplimab Breakthrough Therapy Designation for Cutaneous SCC

FDA Grants Cemiplimab Breakthrough Therapy Designation for Cutaneous SCC

CSCC has the second highest mortality rate among skin cancers after melanoma.

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

Binimetinib a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma.

Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma

Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma

After the second interim analysis, an external data monitoring committee recommended that pembrolizumab be made available to patients receiving ipilimumab whose disease had progressed despite treatment.

Phase 1/2 Study of 6MHP Vaccine and Ipilimumab for Advanced Melanoma

Phase 1/2 Study of 6MHP Vaccine and Ipilimumab for Advanced Melanoma

Researchers are evaluating whether 6MHP, a peptide vaccine, is safe and efficacious when combined with ipilimumab in patients with stage IIIB or higher melanoma.

Higher Opioid Prescription Rates Among Survivors of Cancer

Higher Opioid Prescription Rates Among Survivors of Cancer

Researchers enrolled 17,202 individuals, half of whom were cancer survivors and half of whom were healthy controls, to compare opioid prescription rates between the 2 groups.

Alcohol Intake May Increase Risk for Non-melanoma Skin Cancer

Alcohol Intake May Increase Risk for Non-melanoma Skin Cancer

Researchers reviewed findings from 13 case-control/cohort studies to determine any link between alcohol intake and non-melanoma skin cancer.

Ipilimumab Indication Expanded To Include Pediatric Unresectable or Metastatic Melanoma

Ipilimumab Indication Expanded To Include Pediatric Unresectable or Metastatic Melanoma

The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.

Pembrolizumab Plus Reduced-dose Ipilimumab Safe in Advanced Melanoma

Pembrolizumab Plus Reduced-dose Ipilimumab Safe in Advanced Melanoma

Patients with advanced melanoma may have good outcomes when treated with standard-dose pembrolizumab with 4 doses of reduced-dose ipilimumab.

Nivolumab Does Not Prolong Overall Survival in Advanced Melanoma Post-ipilimumab

Nivolumab Does Not Prolong Overall Survival in Advanced Melanoma Post-ipilimumab

Nivolumab, a monoclonal antibody targeting PD-1, does not improve OS among patients with advanced melanoma whose disease progresses after receiving ipilimumab.

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Talimogene laherparepvec plus ipilimumab improves the overall response rate over ipilimumab alone among patients with unresected, advanced melanoma.

Phase 2 Trial of Poly-ICLC Vaccination for Solid Tumors

Phase 2 Trial of Poly-ICLC Vaccination for Solid Tumors

Researchers are evaluating whether poly-ICLC vaccination is safe and efficacious for patients with melanoma, head and neck cancer, sarcoma, or a non-melanoma skin cancer.

Dabrafenib Plus Trametinib Promising in Melanoma

Dabrafenib Plus Trametinib Promising in Melanoma

Patients with BRAF V600E melanoma and brain metastasis showed intracranial responses when receiving a BRAF (dabrafenib) and a MEK inhibitor (trametinib).

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters